Form 4: Phathom Pharmaceuticals Director Equity Transaction

Director Asit Parikh acquired 24,122 restricted stock units and exercised options for 17,500 shares of Phathom Pharmaceuticals.

Summary

• Director Asit Parikh received a grant of 24,122 restricted stock units (RSUs) on May 19, 2026, under the company's Non-Employee Director Compensation Program.
• The RSUs vest on the earlier of the first anniversary of the grant or the next annual meeting of stockholders.
• Asit Parikh exercised options to acquire 17,500 shares of common stock at an exercise price of $4.95 per share on May 20, 2026.
• Following these transactions, the director holds 52,122 shares directly and 120,500 shares indirectly through a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine disclosure of director equity activity that does not signal a change in company strategy or financial outlook.

Positives

• Director increased direct equity stake in the company through option exercise and RSU grant.
• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting of RSUs is contingent upon the director's continued service on the Board.

Future Outlook

The RSUs are scheduled to vest on the earlier of May 19, 2027, or the date of the next annual stockholders meeting, provided the director remains in service.

Industry Context

StockSavvy.ai notes that routine equity grants and option exercises by board members are standard corporate governance practices intended to align director incentives with long-term shareholder value in the biotechnology sector.

Comparison to Industry Standards

• The use of RSUs for non-employee director compensation is consistent with standard practices among mid-cap biotechnology firms.
• The vesting schedule aligns with typical one-year cliff or annual meeting-based vesting cycles observed in the industry.

Stakeholder Impact

• Increased alignment between board members and shareholders.

Next Steps

• Vesting of the 24,122 RSUs on the earlier of May 19, 2027, or the next annual meeting.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, Insider Trading, Director Compensation, Equity Grant